These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape. Mende CW Adv Ther; 2022 Jan; 39(1):148-164. PubMed ID: 34846711 [TBL] [Abstract][Full Text] [Related]
3. Sodium-Glucose Cotransporter-2 Inhibitors-Miracle Drugs for the Treatment of Chronic Kidney Disease Irrespective of the Diabetes Status: Lessons from the Dedicated Kidney Disease-Focused CREDENCE and DAPA-CKD Trials. Gohda T; Murakoshi M Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430228 [TBL] [Abstract][Full Text] [Related]
4. Sodium-glucose cotransporter 2 inhibition: which patient with chronic kidney disease should be treated in the future? Neuen BL; Jardine MJ; Perkovic V Nephrol Dial Transplant; 2020 Jan; 35(Suppl 1):i48-i55. PubMed ID: 32003833 [TBL] [Abstract][Full Text] [Related]
5. Sodium-Glucose Cotransporter 2 Inhibitors in Patients with Non-Diabetic Chronic Kidney Disease. Mima A Adv Ther; 2021 May; 38(5):2201-2212. PubMed ID: 33860925 [TBL] [Abstract][Full Text] [Related]
6. SGLT2 Inhibition in Type 1 Diabetes with Diabetic Kidney Disease: Potential Cardiorenal Benefits Can Outweigh Preventable Risk of Diabetic Ketoacidosis. Liu H; Sridhar VS; Perkins BA; Rosenstock J; Cherney DZI Curr Diab Rep; 2022 Jul; 22(7):317-332. PubMed ID: 35633439 [TBL] [Abstract][Full Text] [Related]
7. SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. Alicic RZ; Johnson EJ; Tuttle KR Am J Kidney Dis; 2018 Aug; 72(2):267-277. PubMed ID: 29866460 [TBL] [Abstract][Full Text] [Related]
8. Dedicated kidney disease-focused outcome trials with sodium-glucose cotransporter-2 inhibitors: Lessons from CREDENCE and expectations from DAPA-HF, DAPA-CKD, and EMPA-KIDNEY. Rhee JJ; Jardine MJ; Chertow GM; Mahaffey KW Diabetes Obes Metab; 2020 Apr; 22 Suppl 1(Suppl 1):46-54. PubMed ID: 32267076 [TBL] [Abstract][Full Text] [Related]
9. SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Tuttle KR; Brosius FC; Cavender MA; Fioretto P; Fowler KJ; Heerspink HJL; Manley T; McGuire DK; Molitch ME; Mottl AK; Perreault L; Rosas SE; Rossing P; Sola L; Vallon V; Wanner C; Perkovic V Am J Kidney Dis; 2021 Jan; 77(1):94-109. PubMed ID: 33121838 [TBL] [Abstract][Full Text] [Related]
10. Kidney and cardiovascular protection with SGLT2 inhibitors: lessons from cardiovascular outcome trials and CREDENCE. O'Hara DV; Neuen BL; Jardine MJ J Nephrol; 2020 Oct; 33(5):977-983. PubMed ID: 32725496 [TBL] [Abstract][Full Text] [Related]
11. Sodium Glucose Cotransporter-2 Inhibition and Cardiorenal Protection: JACC Review Topic of the Week. Cherney DZ; Odutayo A; Aronson R; Ezekowitz J; Parker JD J Am Coll Cardiol; 2019 Nov; 74(20):2511-2524. PubMed ID: 31727290 [TBL] [Abstract][Full Text] [Related]